<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954381</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002883-26</org_study_id>
    <secondary_id>2011-15</secondary_id>
    <nct_id>NCT01954381</nct_id>
  </id_info>
  <brief_title>Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is one of the most common inflammatory diseases in the general&#xD;
      population and many cardiovascular diseases (valvular, myocardial, pericardial, coronary&#xD;
      disease, stroke, heart failure etc.) have already been described in this disease. Large&#xD;
      epidemiological studies have also demonstrated a higher degree of severity of atherosclerotic&#xD;
      vascular disease in RA patients, to such a degree that several authors have highlighted the&#xD;
      fact that, in the final analysis, the prognosis of RA is rather determined by the severity of&#xD;
      atherosclerotic lesions.&#xD;
&#xD;
      By reducing RA-related systemic inflammation, it can therefore be hypothesized that 24 weeks&#xD;
      of anti-TNF therapy would improve arterial endothelial function and large artery stiffness.&#xD;
&#xD;
      The proposed study will assess the effects of adalimumab therapy on these parameters. A group&#xD;
      of 26 RA patients will be recruited from a rheumatologists association of the French PACA&#xD;
      region (CONCERTO association). This study will be non invasive and will comprise:&#xD;
&#xD;
        -  in vivo study of endothelial function by measuring the post-ischaemic dilatation by 2D&#xD;
           ultrasound;&#xD;
&#xD;
        -  study of large artery stiffness by pulse wave velocity determined by aplannation&#xD;
           tonometry;&#xD;
&#xD;
        -  study of central pulse pressure;&#xD;
&#xD;
        -  evaluation of atherosclerosis-related parameters such as intima-media thickness.&#xD;
&#xD;
      The results obtained should provide a better understanding of the mechanisms involved in&#xD;
      RA-related vascular disease and the effects of anti-TNF therapy.&#xD;
&#xD;
      In view of the high prevalence of RA, this study could potentially interest the medical&#xD;
      community as a whole and could be largely diffused.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the effects of 24 weeks of anti-TNF (adalimumab) therapy on</measure>
    <time_frame>3 YEARS</time_frame>
    <description>- aortic stiffness by measuring carotid-femoral pulse wave velocity (CF-PWV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluate the effects of 24 weeks of anti-TNF (adalimumab) therapy on</measure>
    <time_frame>3 YEARS</time_frame>
    <description>- central pulse pressure (aortic)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluate the effects of 24 weeks of anti-TNF (adalimumab) therapy on</measure>
    <time_frame>3 YEARS</time_frame>
    <description>- endothelial function by studying hyperaemia-induced vasodilation (FMD), reflecting the quality of endothelium-dependent vasorelaxation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the resting blood pressure</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the systolic pressure index</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the structure of the carotid wall</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transthoracic echocardiographic</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Doppler ultrasound.</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 18 years&#xD;
&#xD;
          -  Patients with RA according to ACR 1987 criteria&#xD;
&#xD;
          -  Indication for adalimumab therapy, according to guidelines:&#xD;
&#xD;
          -  moderately to severely active RA, when the response to disease-modifying&#xD;
             anti-rheumatic drugs, including methotrexate, is inadequate,and,severe, active and&#xD;
             active RA in adults not previously treated with methotrexate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minors, pregnant women, not adequate contraception if female with childbearing&#xD;
             potential, majors under guardianship, residents of social welfare or health care&#xD;
             establishments, patients presenting an emergency situation, patients not covered by&#xD;
             French social security, subjects deprived of their freedom and patients refusing to&#xD;
             participate in the clinical research.&#xD;
&#xD;
          -  Absence of informed consent&#xD;
&#xD;
          -  Patients who have previously received anti-TNF therapy&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  History of demyelinising disease&#xD;
&#xD;
          -  Any unstable medical condition&#xD;
&#xD;
          -  Patients with recurrent serious infections&#xD;
&#xD;
          -  History of cardiovascular or cerebrovascular disease&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Patients not having TB prophylaxis as per guidelines for latent TB, or patients&#xD;
             non-treated active tuberculosis&#xD;
&#xD;
          -  Contraindication to adalimumab therapy:&#xD;
&#xD;
               -  Hypersensitivity to adalimumab or one of the excipients.&#xD;
&#xD;
               -  Active tuberculosis or other severe infections such as sepsis and opportunistic&#xD;
                  infections&#xD;
&#xD;
               -  Moderate to severe heart failure .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique h√¥pitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

